GlassScriptPhysician profile
Ronald Earle Howard
NPI 1316940976
$15,772.69
in general payments reported to CMS, 2019-2025
46 companies · $2,686 in 2025
The $2,686 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,051 · 2020: $1,932 · 2021: $3,407 · 2022: $1,696 · 2023: $1,706 · 2024: $3,294 · 2025: $2,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,442 · Education: $206 · Travel and Lodging: $38.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,442.22 |
| Education | $205.99 |
| Travel and Lodging | $38.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,573.60 | 2021-2025 | |
| Allergan, INC. | $1,598.98 | 2019-2022 | |
| Eisai INC. | $1,411.65 | 2020-2025 | |
| Ge Healthcare | $1,368.58 | 2019-2025 | |
| Ucb, INC. | $1,220.29 | 2021-2025 | Briviact, Zilbrysq, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $1,155.67 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amgen INC. | $756.64 | 2019-2022 | |
| Lilly USA, LLC | $650.63 | 2019-2025 | Kisunla, Amyvid, Reyvow |
| Avanir Pharmaceuticals, INC. | $397.94 | 2019-2022 | |
| Lundbeck LLC | $382.92 | 2023-2025 | Vyepti, Rexulti |
| Biogen, INC. | $369.84 | 2020-2025 | Vumerity |
| Alnylam Pharmaceuticals INC. | $364.14 | 2022-2024 | Onpattro |
| Novus Surgical Consultants | $316.25 | 2024 | |
| Novartis Pharmaceuticals Corporation | $270.95 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $263.53 | 2020-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.